Merck itself has acknowledged that long-term exposure to Vioxx can pose a cardiovascular risk.
Vioxx, for instance, got on the market with one proven advantage--it reduced the risk of ulcers.
He has publicly voiced concerns about what the Vioxx debacle means for drug safety.
One of these studies was the one that resulted in Vioxx being pulled from the market.
Before 2000, they say, there was little clinical evidence of a heart risk for Vioxx.
"Merck has been proactive and conscientious in evaluating the cardiovascular profile of rofecoxib (Vioxx), " they write.
The FDA researcher was a steadfast watchdog on drug safety long before the Vioxx recall.
Merck is also conducting such an outcomes trial for Vioxx and its follow-up drug, Arcoxia.
Novartis is taking the bold move of actually comparing its drug to Celebrex and Vioxx.
Investors assumed that sales would flatten, but no one seemed to envisage a Vioxx recall.
The question of the year: Does Merck limit its Vioxx liability by winning several trials?
Merck 's top scientist now says he would consider putting Vioxx back on the market.
Merck yanked Vioxx in 2004 after finding it boosted the risk of heart attacks.
's Vioxx, withdrawn from the market in September because the painkiller boosted heart attack risk.
Judges, seeing thousands of Vioxx cases on their dockets, may push the company to settle.
Twice as many new Vioxx cases are scheduled as have been tried so far.
Two new studies of Vioxx are being widely interpreted as a disaster for Merck.
Then he did back-of-the-envelope calculations that assembled the available data on Celebrex, Bextra and Vioxx.
Gordon's firm already has filed 600 Vioxx cases and expects to file about 2, 500.
But Merck won on all counts, even those related to whether it mismarketed Vioxx.
And the FDA is still scarred by the scandal of Merck 's painkiller Vioxx.
But now he says that fear of Vioxx is keeping investors away from a strong company.
He raised concerns about Merck's Vioxx in 2001, before the drug was yanked from the market.
But after Merck pulled Vioxx in September 2004, Gilmartin faced outside pressure to quit.
Merck hadn't disclosed key results or started a big study to prove Vioxx's safety.
This is what was happening to Vioxx, because of safety concerns, before Merck yanked it.
Concerns had lingered for years that both Vioxx and Celebrex might be linked to heart problems.
In February 2005, a panel of FDA advisors voted to return Vioxx to the market.
In April it said Vioxx could not return and also requested that Pfizer pull Bextra.
Until recently, Vioxx, for arthritis, and Zocor, for cholesterol, delivered much of Merck's growth.
应用推荐